Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective
Open Access
- 31 January 2024
- journal article
- research article
- Published by Springer Nature in International Journal of Obesity
- Vol. 48 (5) , 683-693
Abstract
Objectives: This study aimed to assess the cost-effectiveness of weight-management pharmacotherapies approved by Canada Health, i.e., orlistat, naltrexone 32 mg/bupropion 360 mg (NB-32), liraglutide 3.0 mg and semaglutide 2.4 mg as compared to the current standard of care (SoC). Methods: Analyses were conducted using a cohort with a mean starting age 50 years, body mass index (BMI) 37.5 kg/m2, and 27.6% having type 2 diabetes. Using treatment-specific changes in surrogate endpoints from the STEP trials (BMI, glycemic, blood pressure, lipids), besides a network meta-analysis, the occurrence of weight-related complications, costs, and quality-adjusted life-years (QALYs) were projected over lifetime. Results: From a societal perspective, at a willingness-to-pay (WTP) threshold of CAD 50 000 per QALY, semaglutide 2.4 mg was the most cost-effective treatment, at an incremental cost-utility ratio (ICUR) of CAD 31 243 and CAD 29 014 per QALY gained versus the next best alternative, i.e., orlistat, and SoC, respectively. Semaglutide 2.4 mg extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg and remained cost-effective both under a public and private payer perspective. Results were robust to sensitivity analyses varying post-treatment catch-up rates, longer treatment durations and using real-world cohort characteristics. Semaglutide 2.4 mg was the preferred intervention, with a likelihood of 70% at a WTP threshold of CAD 50 000 per QALY gained. However, when the modeled benefits of weight-loss on cancer, mortality, cardiovascular disease (CVD) or osteoarthritis surgeries were removed simultaneously, orlistat emerged as the best value for money compared with SoC, with an ICUR of CAD 35 723 per QALY gained. Conclusion: Semaglutide 2.4 mg was the most cost-effective treatment alternative compared with D&E or orlistat alone, and extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg. Results were sensitive to the inclusion of the combined benefits of mortality, cancer, CVD, and knee osteoarthritis.Keywords
All Related Versions
This publication has 57 references indexed in Scilit:
- Surrogate outcomes: experiences at the Common Drug ReviewCost Effectiveness and Resource Allocation, 2013
- Body-Mass Index and Mortality among 1.46 Million White AdultsNew England Journal of Medicine, 2010
- The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of EnglandQuality of Life Research, 2009
- A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 DiabetesThe Sleep AHEAD StudyEffect of Weight Loss on Obstructive Sleep ApneaArchives of internal medicine (1960), 2009
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysisBMC Public Health, 2009
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009
- Use of surrogate outcomes in cost-effectiveness models: A review of United Kingdom health technology assessment reportsInternational Journal of Technology Assessment in Health Care, 2009
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Body Mass and Colorectal Cancer Risk in the NIH-AARP CohortAmerican Journal of Epidemiology, 2007
- Primary and subsequent coronary risk appraisal: New results from The Framingham StudyAmerican Heart Journal, 2000